STTK (Shattuck Labs) Forward Dividend Yield %: 0.00% (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STTK Shattuck Labs Inc STTK
42 GF Score
Price $7.42
GF Value $1.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Shattuck Labs Forward Dividend Yield %?

Shattuck Labs STTK +4.80% 42 Forward Dividend Yield % is 0.00% as of Jul. 26, 2026. GuruFocus rates STTK with a GF Score™ of 42/100 and a GF Value™ of $1.05 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 149 Biotechnology companies, Shattuck Labs ranks worse than 671140.27% on this metric.

As of today (2026-07-26), the Forward Annual Dividend Yield of Shattuck Labs is 0.00%.

As of today (2026-07-26), the Trailing Annual Dividend Yield of Shattuck Labs is 0.00%.

STTK's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.42
* Ranked among companies with meaningful Forward Dividend Yield % only.

Shattuck Labs's Dividends per Share for the three months ended in Mar. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Shattuck Labs  (NAS:STTK) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Shattuck Labs Forward Dividend Yield % Related Terms


STTK vs ACHV, CRMD, EIKN: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Shattuck Labs's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shattuck Labs Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shattuck Labs's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Shattuck Labs's Forward Dividend Yield % falls into.


STTK
42GF Score
Shattuck Labs Inc STTK
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shattuck Labs Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Shattuck Labs (STTK) has a Forward Dividend Yield % of 0.00% as of Jul. 26, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Shattuck Labs and its competitors. According to the industry distribution chart, Shattuck Labs ranks #999999 out of 149 companies in the Biotechnology industry.
Is Shattuck Labs' Forward Dividend Yield % too high?
Shattuck Labs' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Shattuck Labs ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shattuck Labs has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shattuck Labs' Forward Dividend Yield % compare to ACHV and CRMD?
According to the Biotechnology industry distribution chart, Shattuck Labs ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Shattuck Labs in the lower half of its industry. The industry median Forward Dividend Yield % is 1.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.42, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Shattuck Labs and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shattuck Labs's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shattuck Labs stock overvalued right now?
Based on GuruFocus' analysis, Shattuck Labs (STTK) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $7.42 — trading 606.7% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Shattuck Labs' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Shattuck Labs (STTK), the current Forward Dividend Yield % is 0.00% as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shattuck Labs (STTK) Overvalued in 2026?

Based on GuruFocus' analysis, Shattuck Labs stock appears to be overvalued. The current stock price of $7.42 is trading 606.7% above its estimated GF Value™ of $1.05. GuruFocus considers Shattuck Labs to be Significantly Overvalued.

Key valuation signals for STTK:

  • Forward Dividend Yield %: 0.00%
  • GF Value™: $1.05 vs. price of $7.42 (606.7% above fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the STTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shattuck Labs Business Description

Address 500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
42GF Score

Get the complete analysis for STTK

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.42
Price
$1.05
GF Value